APD811-301 A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
Grant
Overview
abstract
-
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH. Primary Objective is to compare the effect of ralinepag versus placebo in subjects with standard of care or PAH-specific background therapy on disease progression and achievement of a satisfactory clinical response in subjects with WHO Group 1 PAH.
date/time interval
-
September 2019 - May 2025
awarded by